Studying Glioblastoma with Advanced Imaging and Tissue Analysis
This study aims to improve how we detect and understand glioblastoma (a type of aggressive brain tumor) using a new imaging technique that combines MRI and PET scans. Researchers want to see if this combined imaging, which measures a "glycolytic index" (how much sugar the tumor uses), matches what they find when they test tumor tissue directly. You could be eligible if you are an adult with newly diagnosed or recurrent glioblastoma and are scheduled for surgery to remove the tumor. The study will be considered successful if the imaging measurements strongly match the results from tissue analysis, helping to identify tumor cells that are spreading. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 50 participants. It is not specified if it is randomized, blinded, or what phase it is in.
- What's involved
- You would undergo an FDG-PET scan and about 15 minutes of investigational MR imaging sequences. After these scans, your planned tumor biopsy/resection will occur as part of your standard care.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes, Glycolytic Index and Immunohistochemistry Expression of Glycolytic Molecules, will be measured at two years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Benjamin Ellingson, PhD · PRINCIPAL_INVESTIGATOR · University of California at Los Angeles
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Glycolytic Indextwo years
The Glycolytic Index (GI), ranging from 0 to \~1, will be quantified using a combination of FDG PET and MRI measurements. GI is defined as elevated glucose uptake (18F-FDG standard uptake with respect to lean body mass, SUL), elevated tumor acidity (MTRasym @ 3ppm or MTRRex), and lower oxygen utilization (relative cerebral metabolic rate of oxygen, rCMRO2, defined as R2' x rCBF/rCBV from oxygen-sensitive SAGE-EPI and DSC perfusion), normalized to cell density (using ADC from diffusion MRI, which is inversely proportional to cell density). Average GI within the biopsy area prior to biopsy will be correlated with MCT expression within the sample based on immunohistochemistry stain density of percentage positive cells as the 1st primary outcome measure."
- Immunohistochemistry Expression of Glycolytic Moleculestwo years
MCT expression will be quantified within biopsy samples based on immunohistochemistry stain density of percentage positive cells